MiNK Therapeutics, Inc. ( NASDAQ:INKT – Get Rating ) major shareholder Agenus Inc acquired 22,065 shares of the firm's stock in a transaction on Wednesday, May 10th. The shares were bought at an average cost of $1.51 per share, with a total value of $33,318.15. Following the completion of the acquisition, the insider now owns 21,617,112 shares in the company, valued at $32,641,839.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website .

https://www.dailypolitical.com/2023/05/12/agenus-inc-acquires-22065-shares-of-mink-therapeutics-inc-nasdaqinkt-stock.html

#dailypolitical